Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/30/2025 | $0.39 | Overweight → Equal-Weight | Morgan Stanley |
| 9/30/2025 | Buy → Hold | TD Cowen | |
| 11/30/2021 | $21.00 | Overweight | Morgan Stanley |
| 11/30/2021 | Outperform | Cowen & Co. | |
| 11/30/2021 | $20.00 | Buy | Jefferies |
4 - IO Biotech, Inc. (0001865494) (Issuer)
4 - IO Biotech, Inc. (0001865494) (Issuer)
4 - IO Biotech, Inc. (0001865494) (Issuer)
4 - IO Biotech, Inc. (0001865494) (Issuer)
4 - IO Biotech, Inc. (0001865494) (Issuer)
4 - IO Biotech, Inc. (0001865494) (Issuer)
Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, although statistical significance on the PFS primary endpoint was narrowly missedMeeting scheduled with FDA in December to align on the design of a potential new Phase 3 registrational trial for IO102-IO103 in patients with advanced melanomaPre-clinical data for additional T-win platform pipeline candidates IO112 targeting arginase 1 and IO170 targeting transforming growth factor (TGF)-β were presented at the Society for Immunotherapy of Cancer's (SITC) Annual MeetingEnded the third quarter with appro
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that members of its senior management team will participate in the following upcoming investor conferences: Event: Jefferies Global Healthcare ConferenceLocation: LondonPresentation: Tuesday, November 18, 2025, at 3:00 PM GMT Presenter: Mai-Britt Zocca, PhD, President & CEOWebcast Link: https://wsw.com/webcast/jeff332/iobt/1846538 Event: Piper Sandler 36th Annual Healthcare ConferenceLocation: New YorkFireside chat: Wednesday, December 3, 2025, at 3:00 pm ETPresenter: Mai-Britt Zocc
Pre-clinical data for IO Biotech's next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vaccine-targeted modulation of immunosuppressive myeloid cells, including tumor-associated macrophages (TAMs)Pre-clinical data for IO Biotech's additional T-win vaccine candidate, IO170 targeting Transforming Growth Factor (TGF)-β, demonstrates induction of immune responses that could inhibit tumor growth and reduce lung metastasisData presented at the Society for Immunotherapy of Cancer's Annual Meeting NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage bioph
TD Cowen downgraded IO Biotech from Buy to Hold
Morgan Stanley downgraded IO Biotech from Overweight to Equal-Weight and set a new price target of $0.39
Morgan Stanley initiated coverage of IO Biotech with a rating of Overweight and set a new price target of $21.00
10-Q - IO Biotech, Inc. (0001865494) (Filer)
8-K - IO Biotech, Inc. (0001865494) (Filer)
8-K - IO Biotech, Inc. (0001865494) (Filer)
-- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, completed enrollment in its neoadjuvant/adjuvant Phase 2 basket trial (IOB-032/PN-E40). The trial is studying IO102-IO103, the company's lead investigational therapeutic cancer vaccine candidate, in combination with Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), given before (neoadjuvant) and after (adjuvant) surgery with curative intent in patients with resectab
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company's lead cancer vaccine candidate currently in a pivotal Phase 3 trial. Ms. Shamsaei joins the company's executive team, reporting to IO Biotech CEO Mai-Britt Zocca, Ph.D., and is based in the United States. "Marjan's extensive oncology product commercialization and growth strategy expertise will be invaluable as we progress into the commercia
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company's chief business officer. Dr. Miyara, who has more than 17 years of experience in the pharmaceutical industry, will be responsible for global business development activities including strategic partnerships. Dr. Miyara will be based in the United States, report to IO Biotech's CEO, Mai-Britt Zocca, Ph.D., and be a member of the company's executive team, effective immediately. "We are very excited to welcome
Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77 (CI 0.58-1.00), (p=0.056), with median PFS (mPFS) of 19.4 months vs. 11.0 months, respectively; the results on the primary endpoint narrowly missed the study's statistical significance threshold of p≤0.045 In patients enrolled in this study without prior neo-adjuvant/adjuvant anti-PD-1 treatment (n=371), patients treated with Cylembio plus pembrolizumab achieved improvement in PFS, HR: 0.74 (CI 0.56-0.98) (nominal p=0.037), with mPFS of 24.8 months vs. 11.0 months for the cont
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, 2025, at 8:30 AM ET to disclose the topline results of the pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio (imsapepimut and etimupepimut, adjuvant) in combination with pembrolizumab vs. pembrolizumab alone as a first-line treatment for unresectable or metastatic (advanced) melanoma. Webcast and Conference Call Information The IO Biotech management team will host a webcast/conference call
Enrollment in the company's Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma accelerated in the second half of 2022; the company expects to enroll 75% of patients by mid-2023 and fully enroll the trial by the end of 2023.The Phase 3 trial protocol calls for an interim analysis of overall response rate one year after 75% of patients have been randomized; this interim analysis could allow for submission of a Biologics License Application for an accelerated approval in the United States.The company continues to enroll patients in its Phase 2 basket study (IOB-022/KN-D38) evaluating IO102-IO103 in combination with pembrolizumab in patients with non-small cell lung cancer, head and nec
SC 13G/A - IO Biotech, Inc. (0001865494) (Subject)
SC 13D/A - IO Biotech, Inc. (0001865494) (Subject)
SC 13G/A - IO Biotech, Inc. (0001865494) (Subject)